Today is the last day to apply for Meesho IPO, Exicom IPO and Vidya Bios IPO. Read full analysis: subscription status, category-wise allotment chances, GMP trends, issue size, price band, listing gain expectations and expert views. A complete 1200+ word SEO-optimized IPO report.
Three Major IPOs Closing Today: Complete Analysis of Meesho IPO, Exicom IPO & Vidya Bios IPO (Final Day Guide)
Hello everyone, welcome back. In this detailed report, we will break down three major IPOs that are closing today — Meesho IPO, Exicom IPO, and Vidya Bios IPO.
All three public issues have attracted strong investor interest, and today is the final day to apply.
If you are wondering:
- Which IPO can give the best listing gain?
- Where do you have higher allotment chances?
- What is the latest subscription status?
- What is the current GMP and expected listing price?
Then this fully-detailed, SEO-optimized analysis will help you make the right decision.
Complete Breakdown of All Three IPOs Closing Today
Below, we deep dive into each IPO — fundamentals, issue structure, subscription, allotment chances, GMP and expected returns.
1. Vidya Bios IPO — Final Day Analysis
H3. IPO Basics & Price Band
The Vidya Bios IPO is a fresh issue + OFS mix with a total issue size of approximately ₹300 crore.
Out of this, nearly ₹274 crore is a fresh issue, which means the funds directly help the company expand operations, production capacity and R&D.
- Upper Price Band: ₹52
- Face Value: ₹1
- Lot Size: 288 shares
- Cut-off Time for UPI: 5:00 PM
- Netbanking Cut-off: varies from bank to bank (usually 3–4 PM)
If you apply today, make sure you approve the UPI mandate before the deadline.
Category-Wise Allotment Allocation
The share allocation for the Vidya Bios IPO is:
- 50% — QIBs
- 35% — Retail Investors
- 15% — NII / HNI Category
This IPO offers the highest retail quota among all three issues today.
Subscription Status (Updated)
The latest subscription numbers show:
- QIB: 1.43×
- NII (Small + Big): Around 23×
- Big NII: ~19–20×
- Retail: 18.17×
- Total Subscription: ~14×
The response is strong across categories, especially among NIIs.
Allotment Chances
- Best chances: Big HNI Category
- Moderate chances: Retail category
- Lowest chances: Small HNI
In retail, roughly 1 allotment out of 30 applications is expected.
GMP & Expected Listing Gain
The current GMP is around 11%, which is the lowest among the three IPOs closing today.
Still, if QIB demand increases in the last hour, there could be a positive push.
Expected listing gain: 5–12%
This makes Vidya Bios more suitable for moderate listing gain + short-term holding (6–12 months).
2. Exicom IPO — Strong Demand, Good GMP, High Oversubscription
H3. IPO Size & Structure
The Exicom Power Solutions IPO has a much larger issue size:
- Total Issue Size: ₹922 crore
- Fresh Issue: ₹670 crore
- OFS: ₹252 crore
Exicom is one of India’s major EV charging infrastructure companies, making it attractive for long-term investors.
Price Band & Lot Size
- Face Value: ₹10
- Upper Price Band: ₹124
- Lot Size: 120 shares
Category-Wise Allocation
- 75% — QIB
- 15% — NII
- 10% — Retail
Because retail is only 10%, allotment chances for retail investors are relatively low.
Subscription Status (Updated)
The subscription numbers show massive interest:
- QIB: 0.88× (expected to jump sharply by end of day)
- NII (Total): ~38.58×
- Big NII: ~35×
- Retail: ~49×
- Total Subscription: ~19.91×
This IPO has seen heavy bidding from HNIs and retail investors.
Allotment Chances
- Highest chances: Big HNI
- Moderate chances: Small HNI
- Very low chances: Retail (due to oversubscription 49×)
GMP & Expected Listing Gain
Current GMP is around 34% premium.
Expected listing gain: 30–40%
Expected profit per lot (retail): ₹4,500–₹5,000
This IPO is ideal for listing gain hunters.
3. Meesho IPO — The Most Awaited & Most Subscribed IPO of the Day
H3. IPO Overview
The Meesho IPO has created the biggest buzz in the market.
It is attracting record-level QIB interest due to Meesho’s strong digital marketplace model and profitability trends.
- Face Value: ₹1
- Upper Price Band: ₹111
- Lot Size: 135 shares
- Total Issue Size: Around ₹5,421 crore
The allocation structure:
- 75% — QIB
- 15% — NII
- 10% — Retail
Subscription Status (Updated)
Meesho IPO has received the strongest subscription among all three:
- QIB: 10× (expected to create a new record)
- NII Total: 20.49×
- Big NII: 21.51×
- Small NII: 18.47×
- Retail: 12.79×
- Total Subscription: 13.51×
QIB subscription alone has crossed ₹16,670 crore in bids — a massive figure.
Allotment Chances
- Highest chances: Big HNI
- Moderate chances: Retail
- Lowest chances: Small HNI
Although retail is heavily subscribed, the larger issue size slightly increases chances compared to Exicom.
GMP & Listing Gain Predictions
Meesho currently shows a strong GMP of ₹48.
Expected listing price:
₹111 + ₹48 = ₹159 per share
Expected listing gain: 43%+
Expected profit per lot: ₹6,000–₹6,500
Meesho stands out as the best IPO for listing gains today.
Final Comparison — Which IPO Should You Apply For?
Below is a quick ranking based on listing gain potential:
1. Meesho IPO — Top Priority
✔ Highest GMP
✔ Strongest QIB demand
✔ Best listing gain potential
✔ Bigger issue size = slightly better allotment probability
2. Exicom IPO — Second Priority
✔ Strong oversubscription
✔ EV charging theme
✔ 30–40% expected listing gain
✘ Very tough allotment chances for retail
3. Vidya Bios IPO — Third Priority
✔ Good for moderate listing gain
✔ Could gain if QIB demand rises
✘ Lowest GMP among the three
✔ Best chances for retail allotment (35% quota)
Conclusion: Should You Apply in All Three IPOs?
If your objective is listing gains, the recommended order is:
- Meesho IPO
- Exicom IPO
- Vidya Bios IPO
If your goal is higher allotment probability, the order becomes:
- Vidya Bios IPO
- Meesho IPO
- Exicom IPO
All three IPOs have strong fundamentals and investor demand, but Meesho IPO clearly stands out due to its massive QIB subscription and stronger GMP.
If you have the capital, applying in all three IPOs increases your probability of at least one successful allotment.
You may share your thoughts, doubts, or ask for a YouTube voiceover script, thumbnail text, or infographics summarizing this report.